Subscribe to Newsletter
Manufacture Business Practice, Drug Delivery, Ingredients, Quality & Compliance, Small Molecules, Trends & Forecasts

Characterization of IgG monomers & their aggregates

sponsored by Malvern Panalytical


In biopharmaceutical formulations one of the key factors that manufacturers need to understand is the propensity of their samples to aggregate. Aggregates in biologic drugs are undesirable for two reasons. They reduce the amount of active ingredient in the sample, thereby reducing efficacy, and they can stimulate immunogenic responses in the body. This in turn can lead to more rapid clearance of the drug and again reduce efficacy, or in some cases can lead to severe immune responses. Full characterization of protein drug samples is therefore necessary both for those developing formulations and those characterizing final products. It is therefore extremely important to have a technique which can both measure the amount of different protein aggregate components and identify and characterize each of them. In this way a sample can be fully characterized and understood.

Receive content, products, events as well as relevant industry updates from The Medicine Maker and its sponsors.
Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine